Unknown

Dataset Information

0

Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.


ABSTRACT: Recent advances in sarcoma genomics have identified novel mutations in the PI3K pathway in human sarcomas. Here, we use a mouse model of primary soft-tissue sarcoma for preclinical testing of doxorubicin and inhibitors of the PI3K pathway: BKM120 (PI3K inhibitor) and BEZ235 (a dual PI3K/mTOR inhibitor). Doxorubicin-treated tumors (n = 15) showed a partial response rate of 6.6%, just as the majority of human sarcomas do not respond to doxorubicin. Treatment with BKM120 elicited a partial response in 50% of tumors (n = 10), which was also seen in combination with doxorubicin (n = 10). Additionally, BKM120 treatment produced a robust delay in tumor growth kinetics. BEZ235-treated tumors (n = 9) showed a complete response rate of 11.1%. Combining BEZ235 with doxorubicin (n = 10) increased the complete response rate to 50% (P = 0.035). These studies demonstrate that PI3K pathway inhibition is a viable and attractive target for soft-tissue sarcomas.

SUBMITTER: Kim S 

PROVIDER: S-EPMC3350993 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2010-03-03 | E-GEOD-16779 | biostudies-arrayexpress
2009-11-21 | GSE16779 | GEO
| S-EPMC2779485 | biostudies-literature
| S-EPMC7545231 | biostudies-literature
| S-EPMC6262133 | biostudies-literature
| S-EPMC6058400 | biostudies-literature
2014-12-01 | GSE20049 | GEO
| S-EPMC5678691 | biostudies-literature
| S-EPMC5571905 | biostudies-literature
| S-EPMC5771963 | biostudies-literature